Sort   by:  
 Page size 
ProteomicsCSF proteomics of aducanumab treated APP-SAA triple knock-in mice
Anti-amyloid β-peptide (Aβ) immunotherapy was developed as treatment for Alzheimer’s disease to reduce and prevent amyloid plaque pathology and its downstream consequences. Efficient amyloid plaque clearance has been proven in clinical trials with Aducanumab, Lecanemab and Donanemab. At least two of...
ORGANISM(S): Mus musculus (Mouse) 
2025-08-25 | PXD061932 | Pride
Cerebrospinal fluid Mouse Diapasef Aducanumab 
GenomicsscRNAseq of Cd45+ cells from brains of Aducanumab-treated ApoE-variant Alzheimer's mice
scRNAseq of Cd45+ cells from brains of Aducanumab-treated ApoE-variant Alzheimer's mice
PRJNA1001860 | ENA
ProteomicsData in support of Anti-Aβ antibody treatment with Aducanumab modified the proteome of senile plaques and surrounding tissue and altered disease progression in a transgenic mouse model of Alzheimer’s disease.
Alzheimer’s disease (AD) is the most comment type of dementia and is characterized by neuronal loss and cognitive decline. Aggregation and accumulation of Aβ proteoforms into senile plaques (SP) is one of the key hallmarks of the disease. The accumulation of Aβ in particular in hippocampus has been ...
ORGANISM(S): Mus musculus (Mouse) 
2021-03-25 | PXD021918 | Pride
Pasef Ad Proteomics A-beta 
TranscriptomicsscRNAseq of Cd45+ cells from brains of Aducanumab-treated ApoE-variant Alzheimer's mice
Here we perform single cell sequencing to examine the impact of aducanumab treatment on the transcriptome of immune cells of aged AD mice bearing knock-in of human APOE variants in the murine APOE locus, treated either with aducanumab or an IgG control.
ORGANISM(S): Mus musculus 
2023-12-29 | GSE239975 | GEO
Genomics
Aducanumab Fc dead bulk RNAseq
PRJNA1173718 | ENA
TranscriptomicsChronic Aducanumab-mediated clearance of amyloid plaques decreases microglial activation and induces a unique microglial phenotype associated with antigen presentation
Anti-amyloid β-peptide (Aβ) immune therapy was developed as treatment for Alzheimer’s disease (AD) to reduce and prevent amyloid plaque pathology. This approach has proven successful in phase 3 clinical trials of Aducanumab, Lecanemab and Donanemab. These antibodies induce robust amyloid plaque clea...
ORGANISM(S): Mus musculus 
2025-08-20 | GSE288801 | GEO
Genomics
Aducanumab treatment with APP/PS1 mice
PRJNA1026618 | ENA
GenomicsChronic Aducanumab-mediated clearance of amyloid plaques decreases microglial activation and induces a unique microglial phenotype associated with antigen presentation
Chronic Aducanumab-mediated clearance of amyloid plaques decreases microglial activation and induces a unique microglial phenotype associated with antigen presentation
PRJNA1219494 | ENA
UnknownAn insider's perspective on FDA approval of aducanumab.
Not available
S-EPMC10193636 | biostudies-literature
UnknownImmunotherapy with Aducanumab Restores Calcium Homeostasis in Tg2576 Mice.
Not available
S-EPMC5157102 | biostudies-literature
Sort   by:  
 Page size